CR20130281A - Compuesto bicíclico - Google Patents

Compuesto bicíclico

Info

Publication number
CR20130281A
CR20130281A CR20130281A CR20130281A CR20130281A CR 20130281 A CR20130281 A CR 20130281A CR 20130281 A CR20130281 A CR 20130281A CR 20130281 A CR20130281 A CR 20130281A CR 20130281 A CR20130281 A CR 20130281A
Authority
CR
Costa Rica
Prior art keywords
bicyclic compound
compound
acc
obesity
diabetes
Prior art date
Application number
CR20130281A
Other languages
English (en)
Spanish (es)
Inventor
Tsuneo Yasuma
Makoto Kamata
Tohru Yamashita
Hideki Hirose
Masataka Murakami
Asato Kina
Kazuko Yonemori
Ryo Mizojiri
Ikuo Fujimori
Takuya Fujimoto
Zenichi Ikeda
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of CR20130281A publication Critical patent/CR20130281A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/423Oxazoles condensed with carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CR20130281A 2010-11-30 2013-06-11 Compuesto bicíclico CR20130281A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010266097 2010-11-30
JP2011175330 2011-08-10

Publications (1)

Publication Number Publication Date
CR20130281A true CR20130281A (es) 2013-10-07

Family

ID=45418740

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130281A CR20130281A (es) 2010-11-30 2013-06-11 Compuesto bicíclico

Country Status (24)

Country Link
US (1) US8729102B2 (cg-RX-API-DMAC7.html)
EP (1) EP2649062B1 (cg-RX-API-DMAC7.html)
JP (1) JP5824517B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140001965A (cg-RX-API-DMAC7.html)
CN (1) CN103347872B (cg-RX-API-DMAC7.html)
AR (1) AR084032A1 (cg-RX-API-DMAC7.html)
AU (1) AU2011337565A1 (cg-RX-API-DMAC7.html)
BR (1) BR112013013417A2 (cg-RX-API-DMAC7.html)
CA (1) CA2819400A1 (cg-RX-API-DMAC7.html)
CL (1) CL2013001520A1 (cg-RX-API-DMAC7.html)
CO (1) CO6751239A2 (cg-RX-API-DMAC7.html)
CR (1) CR20130281A (cg-RX-API-DMAC7.html)
DO (1) DOP2013000118A (cg-RX-API-DMAC7.html)
EA (1) EA201390794A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP13012719A (cg-RX-API-DMAC7.html)
ES (1) ES2536319T3 (cg-RX-API-DMAC7.html)
MA (1) MA34713B1 (cg-RX-API-DMAC7.html)
MX (1) MX2013006113A (cg-RX-API-DMAC7.html)
PE (1) PE20140161A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013501099A1 (cg-RX-API-DMAC7.html)
SG (1) SG190925A1 (cg-RX-API-DMAC7.html)
TW (1) TW201242951A (cg-RX-API-DMAC7.html)
UY (1) UY33756A (cg-RX-API-DMAC7.html)
WO (1) WO2012074126A1 (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011246004A1 (en) 2010-04-27 2012-11-29 Takeda Pharmaceutical Company Limited Bicyclic compound derivatives and their use as ACC inhibitors.
WO2013061962A1 (ja) 2011-10-24 2013-05-02 武田薬品工業株式会社 二環性化合物
WO2014088983A1 (en) 2012-12-07 2014-06-12 Merck Sharp & Dohme Corp. Regioselective n-2 arylation of indazoles
PL403149A1 (pl) * 2013-03-14 2014-09-15 Celon Pharma Spółka Akcyjna Nowe związki pochodne pirazolilobenzo[d]imidazolu
CN105358143B (zh) 2013-05-10 2019-01-22 吉利德阿波罗公司 Acc抑制剂和其用途
US10208044B2 (en) 2013-05-10 2019-02-19 Gilead Apollo, Llc ACC inhibitors and uses thereof
HK1221661A1 (zh) * 2013-05-10 2017-06-09 Gilead Apollo, Llc Acc抑制剂和其用途
KR20160007598A (ko) 2013-05-10 2016-01-20 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
BR112016004118A2 (pt) 2013-09-12 2017-10-17 Pfizer uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar
JP6352415B2 (ja) 2013-11-14 2018-07-04 カディラ・ヘルスケア・リミテッド 新規なヘテロ環化合物
US10689383B2 (en) 2014-08-04 2020-06-23 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CN107108534B (zh) * 2014-08-29 2023-05-09 Chdi基金会股份有限公司 用于成像亨廷顿蛋白的探针
JP2016079168A (ja) * 2014-10-17 2016-05-16 塩野義製薬株式会社 9員縮合環誘導体
CN104447725B (zh) * 2014-10-22 2018-02-02 浙江大学 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法
WO2016130501A1 (en) 2015-02-09 2016-08-18 Incyte Corporation Aza-heteroaryl compounds as pi3k-gamma inhibitors
AU2016332021A1 (en) * 2015-09-29 2018-04-19 Oncotherapy Science, Inc. Bicyclic compound and use thereof for inhibiting SUV39H2
CN105601626A (zh) * 2015-11-04 2016-05-25 浙江大学 一种含2-取代噁唑啉衍生物的制备方法
PT3371190T (pt) 2015-11-06 2022-07-08 Incyte Corp Compostos heterocíclicos como inibidores de pi3k-gamma
US20170190689A1 (en) 2016-01-05 2017-07-06 Incyte Corporation Pyridine and pyridimine compounds as pi3k-gamma inhibitors
TW201803871A (zh) 2016-06-24 2018-02-01 英塞特公司 作為PI3K-γ抑制劑之雜環化合物
JP7179014B2 (ja) 2017-04-24 2022-11-28 テサロ, インコーポレイテッド ニラパリブの製造方法
CN118063470A (zh) 2017-10-18 2024-05-24 因赛特公司 作为PI3K-γ抑制剂的由叔羟基取代的缩合咪唑衍生物
CR20250050A (es) 2018-09-05 2025-03-19 Incyte Corp Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165)
MX2022007265A (es) 2019-12-20 2022-09-09 Nuevolution As Compuestos activos frente a receptores nucleares.
PE20230240A1 (es) 2019-12-20 2023-02-07 Nuevolution As Compuestos activos frente a receptores nucleares
JP7713954B2 (ja) 2020-03-31 2025-07-28 ヌエヴォリューション・アクティーゼルスカブ 核内受容体に対して活性な化合物
AU2021245397A1 (en) 2020-03-31 2022-10-20 Nuevolution A/S Compounds active towards nuclear receptors
EP4434520A4 (en) 2021-11-19 2025-10-29 Shionogi & Co PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE
AR129265A1 (es) 2022-05-12 2024-08-07 Syngenta Crop Protection Ag Compuestos de alcoxi-heteroaril-carboxamida o tioamida
WO2024033374A1 (en) 2022-08-11 2024-02-15 Syngenta Crop Protection Ag Novel arylcarboxamide or arylthioamide compounds
WO2024126650A1 (en) 2022-12-15 2024-06-20 Syngenta Crop Protection Ag Novel bicyclic-carboxamide compounds useful as pesticides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
EP1027051B1 (en) * 1997-04-30 2005-01-05 Eli Lilly And Company Antithrombotic agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
AU2001252596A1 (en) 2000-04-28 2001-11-12 Takeda Chemical Industries Ltd. Melanin concentrating hormone antagonists
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
US20030187023A1 (en) 2000-07-17 2003-10-02 Keiji Kubo Sulfone derivatives, process for their production and use thereof
JP4468810B2 (ja) * 2002-07-24 2010-05-26 キューエルティー インコーポレーティッド ピラゾリルベンゾチアゾール誘導体および治療薬としてのそれらの使用法
PE20040609A1 (es) 2002-11-01 2004-10-29 Takeda Pharmaceutical Compuestos heterociclicos aromaticos como promotores de un factor neurotrofico
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
WO2004048363A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited イミダゾール誘導体、その製造法および用途
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
JP4769082B2 (ja) 2003-12-17 2011-09-07 武田薬品工業株式会社 ウレア誘導体、その製造法及び用途
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
EP1726580A4 (en) 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
EP2308839B1 (en) 2005-04-20 2017-03-01 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1911738A4 (en) 2005-07-29 2009-12-16 Takeda Pharmaceutical COMPOUND OF PHENOXYALKANOIC ACID
TW200740435A (en) 2005-08-10 2007-11-01 Takeda Pharmaceuticals Co Therapeutic agent for diabetes
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
EP1996567B1 (en) * 2006-02-15 2013-09-18 AbbVie Inc. Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
DK2041123T3 (da) 2006-06-27 2012-05-07 Takeda Pharmaceutical Kondenserede cykliske forbindelser.
JP5306818B2 (ja) 2006-10-18 2013-10-02 武田薬品工業株式会社 縮合複素環化合物
MX2009003972A (es) 2006-10-19 2009-04-27 Takeda Pharmaceutical Compuesto de indol.
WO2008093639A1 (ja) 2007-01-29 2008-08-07 Takeda Pharmaceutical Company Limited ピラゾール化合物
US20110009384A1 (en) 2007-02-09 2011-01-13 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
US8318746B2 (en) 2007-04-27 2012-11-27 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
EP2157859A4 (en) 2007-06-19 2011-01-12 Takeda Pharmaceutical INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
WO2010118009A1 (en) * 2009-04-06 2010-10-14 Ptc Therapeutics, Inc. Hcv inhibitor and therapeutic agent combinations
AU2011246004A1 (en) 2010-04-27 2012-11-29 Takeda Pharmaceutical Company Limited Bicyclic compound derivatives and their use as ACC inhibitors.
WO2012108478A1 (ja) 2011-02-09 2012-08-16 武田薬品工業株式会社 単環化合物

Also Published As

Publication number Publication date
WO2012074126A1 (en) 2012-06-07
US20120142714A1 (en) 2012-06-07
AU2011337565A1 (en) 2013-07-11
JP5824517B2 (ja) 2015-11-25
MX2013006113A (es) 2013-11-01
AR084032A1 (es) 2013-04-17
EP2649062A1 (en) 2013-10-16
CO6751239A2 (es) 2013-09-16
PH12013501099A1 (en) 2013-07-08
WO2012074126A9 (en) 2013-06-06
KR20140001965A (ko) 2014-01-07
JP2013545718A (ja) 2013-12-26
MA34713B1 (fr) 2013-12-03
TW201242951A (en) 2012-11-01
CA2819400A1 (en) 2012-06-07
CN103347872B (zh) 2014-12-24
DOP2013000118A (es) 2013-09-30
AU2011337565A2 (en) 2013-07-11
BR112013013417A2 (pt) 2019-09-24
SG190925A1 (en) 2013-07-31
EA201390794A1 (ru) 2013-11-29
PE20140161A1 (es) 2014-02-19
CN103347872A (zh) 2013-10-09
ECSP13012719A (es) 2013-12-31
EP2649062B1 (en) 2015-04-08
CL2013001520A1 (es) 2013-10-18
US8729102B2 (en) 2014-05-20
ES2536319T3 (es) 2015-05-22
UY33756A (es) 2012-06-29

Similar Documents

Publication Publication Date Title
CR20130281A (es) Compuesto bicíclico
CR20110440A (es) Compuestos de piridazinona
CR20130024A (es) Compuestos heterocíclicos fusionados
CR10991A (es) Compuestos anulares fusionados como antagonistas parciales de ppar-gamma
UY32551A (es) Compuestos peptidomiméticos de sulfamida y usos antivirales de los mismos
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CR20150217A (es) Inhibidores de histona demetilasas
MX393610B (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres
CL2014002873A1 (es) Compuestos derivados de pirimidin-amina o triazin-amina, inhibidores de adn-pk; composicion farmaceutica; y su uso para el tratamiento del cancer.
UY35821A (es) Compuesto heterocíclico
UY32554A (es) Compuestos peptidomiméticos de sulfonamida y usos antivirales de los mismos
CO6640253A2 (es) Derivados de compuesto biciclico y su uso como inhibidores de acc
MX2015015416A (es) Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
ECSP19077969A (es) Compuesto heterociclico
DOP2016000253A (es) Nuevos compuestos
MX2017000222A (es) Metodos y composiciones para tratar la obesidad, prevenir el aumento de peso, promover la perdida de peso, promover el adelgazamiento o tratar o prevenir el desarrollo de la diabetes.
IN2014DN10574A (cg-RX-API-DMAC7.html)
GT201300041A (es) Composicion fungicida sinergista
BR112014021068A2 (pt) Inibidor de uma interação entre fosfatidilserina e um receptor tim, composição farmacêutica e uso de um inibidor
PH12016501096A1 (en) SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
PH12015502023B1 (en) Guanidinobenzoic acid ester compound
ECSP099836A (es) Macrociclos y sus usos
CL2012001758A1 (es) Uso de compuestos derivados de 8-hidroxiquinolin-7-carboxamida y sus sales, para el tratamiento y/o prevencion de infecciones fungicas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)